Clostridium Diagnostics
Global Clostridium Diagnostics Market to Reach $4.7 Billion by 2027
Amid the COVID-19 crisis, the global market for Clostridium Diagnostics estimated at US$1.9 Billion in the year 2020, is projected to reach a revised size of US$4.7 Billion by 2027, growing at aCAGR of 13.9% over the period 2020-2027. Immunoassays, one of the segments analyzed in the report, is projected to record 15.4% CAGR and reach US$3.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Molecular Diagnostics segment is readjusted to a revised 9.5% CAGR for the next 7-year period.
The U.S. Market is Estimated at $512.3 Million, While China is Forecast to Grow at 18.4% CAGR
The Clostridium Diagnostics market in the U.S. is estimated at US$512.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2027 trailing a CAGR of 18.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.6% and 12.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.9% CAGR.
Select Competitors (Total 42 Featured) -
- Abbott Laboratories
- Beckman Coulter, Inc.
- Becton, Dickinson & Company
- bioMerieux SA
- Chrono-log Corporation
- Corgenix
- Diazyme Laboratories
- F. Hoffmann-La Roche AG
- Fujirebio US, Inc.
- Hologic, Inc.
- QIAGEN GmbH
- Siemens Healthineers
- Sysmex Corporation
- Thermo Fisher Scientific, Inc.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS
- 3.
MARKET TRENDS & DRIVERS DRIVERS - 4.
GLOBAL MARKET PERSPECTIVE- TABLE 1: World Current & Future Analysis for Clostridium Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 2: World Historic Review for Clostridium Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 3: World 15-Year Perspective for Clostridium Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
- TABLE 4: World Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 5: World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 6: World 15-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- TABLE 7: World Current & Future Analysis for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 8: World Historic Review for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 9: World 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- TABLE 10: World Current & Future Analysis for Clostridium difficile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 11: World Historic Review for Clostridium difficile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 12: World 15-Year Perspective for Clostridium difficile by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- TABLE 13: World Current & Future Analysis for Clostridium perfringens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 14: World Historic Review for Clostridium perfringens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 15: World 15-Year Perspective for Clostridium perfringens by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- TABLE 16: World Current & Future Analysis for Clostridium botulinum by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 17: World Historic Review for Clostridium botulinum by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 18: World 15-Year Perspective for Clostridium botulinum by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- TABLE 19: World Current & Future Analysis for Clostridium tetani by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 20: World Historic Review for Clostridium tetani by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 21: World 15-Year Perspective for Clostridium tetani by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- TABLE 22: World Current & Future Analysis for Clostridium sordellii by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 23: World Historic Review for Clostridium sordellii by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 24: World 15-Year Perspective for Clostridium sordellii by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- TABLE 25: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 26: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 27: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- TABLE 28: World Current & Future Analysis for Independent Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 29: World Historic Review for Independent Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 30: World 15-Year Perspective for Independent Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- TABLE 31: World Current & Future Analysis for Physicians Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 32: World Historic Review for Physicians Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 33: World 15-Year Perspective for Physicians Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
- III. MARKET ANALYSIS
- UNITED STATES
- TABLE 34: USA Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 35: USA Historic Review for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 36: USA 15-Year Perspective for Clostridium Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunoassays and Molecular Diagnostics for the Years 2012, 2020 & 2027
- TABLE 37: USA Current & Future Analysis for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 38: USA Historic Review for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 39: USA 15-Year Perspective for Clostridium Diagnostics by Bacterial Strain - Percentage Breakdown of Value Sales for Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii for the Years 2012, 2020 & 2027
- TABLE 40: USA Current & Future Analysis for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 41: USA Historic Review for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 42: USA 15-Year Perspective for Clostridium Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Independent Laboratories and Physicians Clinics for the Years 2012, 2020 & 2027
- CANADA
- TABLE 43: Canada Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 44: Canada Historic Review for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 45: Canada 15-Year Perspective for Clostridium Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunoassays and Molecular Diagnostics for the Years 2012, 2020 & 2027
- TABLE 46: Canada Current & Future Analysis for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 47: Canada Historic Review for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 48: Canada 15-Year Perspective for Clostridium Diagnostics by Bacterial Strain - Percentage Breakdown of Value Sales for Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii for the Years 2012, 2020 & 2027
- TABLE 49: Canada Current & Future Analysis for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 50: Canada Historic Review for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 51: Canada 15-Year Perspective for Clostridium Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Independent Laboratories and Physicians Clinics for the Years 2012, 2020 & 2027
- JAPAN
- TABLE 52: Japan Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 53: Japan Historic Review for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 54: Japan 15-Year Perspective for Clostridium Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunoassays and Molecular Diagnostics for the Years 2012, 2020 & 2027
- TABLE 55: Japan Current & Future Analysis for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 56: Japan Historic Review for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 57: Japan 15-Year Perspective for Clostridium Diagnostics by Bacterial Strain - Percentage Breakdown of Value Sales for Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii for the Years 2012, 2020 & 2027
- TABLE 58: Japan Current & Future Analysis for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 59: Japan Historic Review for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 60: Japan 15-Year Perspective for Clostridium Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Independent Laboratories and Physicians Clinics for the Years 2012, 2020 & 2027
- CHINA
- TABLE 61: China Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 62: China Historic Review for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 63: China 15-Year Perspective for Clostridium Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunoassays and Molecular Diagnostics for the Years 2012, 2020 & 2027
- TABLE 64: China Current & Future Analysis for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 65: China Historic Review for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 66: China 15-Year Perspective for Clostridium Diagnostics by Bacterial Strain - Percentage Breakdown of Value Sales for Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii for the Years 2012, 2020 & 2027
- TABLE 67: China Current & Future Analysis for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 68: China Historic Review for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 69: China 15-Year Perspective for Clostridium Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Independent Laboratories and Physicians Clinics for the Years 2012, 2020 & 2027
- EUROPE
- TABLE 70: Europe Current & Future Analysis for Clostridium Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
- TABLE 71: Europe Historic Review for Clostridium Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 72: Europe 15-Year Perspective for Clostridium Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
- TABLE 73: Europe Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 74: Europe Historic Review for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 75: Europe 15-Year Perspective for Clostridium Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunoassays and Molecular Diagnostics for the Years 2012, 2020 & 2027
- TABLE 76: Europe Current & Future Analysis for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 77: Europe Historic Review for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 78: Europe 15-Year Perspective for Clostridium Diagnostics by Bacterial Strain - Percentage Breakdown of Value Sales for Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii for the Years 2012, 2020 & 2027
- TABLE 79: Europe Current & Future Analysis for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 80: Europe Historic Review for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 81: Europe 15-Year Perspective for Clostridium Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Independent Laboratories and Physicians Clinics for the Years 2012, 2020 & 2027
- FRANCE
- TABLE 82: France Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 83: France Historic Review for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 84: France 15-Year Perspective for Clostridium Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunoassays and Molecular Diagnostics for the Years 2012, 2020 & 2027
- TABLE 85: France Current & Future Analysis for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 86: France Historic Review for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 87: France 15-Year Perspective for Clostridium Diagnostics by Bacterial Strain - Percentage Breakdown of Value Sales for Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii for the Years 2012, 2020 & 2027
- TABLE 88: France Current & Future Analysis for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 89: France Historic Review for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 90: France 15-Year Perspective for Clostridium Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Independent Laboratories and Physicians Clinics for the Years 2012, 2020 & 2027
- GERMANY
- TABLE 91: Germany Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 92: Germany Historic Review for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 93: Germany 15-Year Perspective for Clostridium Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunoassays and Molecular Diagnostics for the Years 2012, 2020 & 2027
- TABLE 94: Germany Current & Future Analysis for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 95: Germany Historic Review for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 96: Germany 15-Year Perspective for Clostridium Diagnostics by Bacterial Strain - Percentage Breakdown of Value Sales for Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii for the Years 2012, 2020 & 2027
- TABLE 97: Germany Current & Future Analysis for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
- TABLE 98: Germany Historic Review for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
- TABLE 99: Germany 15-Year Perspective for Clostridium Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Independent Laboratories and Physicians Clinics for the Years 2012, 2020 & 2027
- ITALY
- TABLE 100: Italy Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR